ArticleFrontiers in medicine2026
Adjunctive diagnostic utility of POU2F3 in predominantly pulmonary high-grade neuroendocrine carcinomas with limited or discordant conventional marker expression: a case-control study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis of high-grade neuroendocrine carcinoma may be challenging when conventional neuroendocrine markers show limited or discordant expression. POU2F3 is associated with a neuroendocrine-low subset of small cell carcinoma, but its incremental contribution in routine diagnostic practice remains incompletely defined. Objective: To evaluate the adjunctive diagnostic utility of POU2F3 in predominantly pulmonary high-grade neuroendocrine carcinomas, particularly in cases with limited or discordant conventional marker expression. Methods: This retrospective case-control study included 140 neuroendocrine carcinomas and 100 poorly differentiated non-neuroendocrine controls. POU2F3 expression was assessed in biopsy and resection specimens and analyzed according to histological subtype, chromogranin A status, marker-discordant status, and diagnostic-panel interpretation. Diagnostic performance was reported with 95% confidence intervals, and paired changes after incorporation of POU2F3 were evaluated using the exact McNemar test. Results: POU2F3 was positive in 28 of 140 neuroendocrine carcinomas and 2 of 100 controls. Positivity was more frequent in chromogranin A-negative/low than in chromogranin A-positive neuroendocrine carcinomas (34.5% vs. 10.6%; odds ratio, 4.46; 95% confidence interval, 1.84-10.82; Conclusion: POU2F3 has limited stand-alone sensitivity but provides incremental diagnostic support in selected neuroendocrine carcinomas with limited or discordant conventional marker expression. It should be used selectively and interpreted together with morphology and established neuroendocrine markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.